Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Tabrecta (capmatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)

Drug Name

Tabrecta™ (capmatinib)

Developer

Novartis Pharmaceuticals

Therapy Class

Mesenchymal-epithelial transition (MET) inhibitor

Product Description

Film-coated tablets

Current Indication

Non-small cell lung cancer (NSCLC)

Market Sector

Oncology

Development Status

Approved in the US and Japan
Expand
Close
Close
Close

Go Top